SC
ACER

Sophrosyne Capital’s Acer Therapeutics Inc ACER Stock Holding History

Sophrosyne Capital’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,400
Closed -$366K – 91
2013
Q4 		$366K Buy
+2,400
New +$391K 0.32% 39

Other funds holding ACER

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Sophrosyne Capital's ACER Position: Q1 2014 in Review

Sophrosyne Capital sold out of Acer Therapeutics Inc (ACER) in Q1 2014, closing a stake of 2,400 shares — an estimated $366K sold.

Sophrosyne Capital first reported a position in ACER in Q4 2013 and held it in 1 quarter. The position peaked at $366K in Q4 2013. 18 funds tracked by Wall St. Rank hold ACER as of Q1 2014.

  • Sophrosyne Capital reported no remaining Acer Therapeutics Inc position as of Q1 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 2,400 Acer Therapeutics Inc shares in Q1 2014, an estimated $366K.
  • Sophrosyne Capital first reported a position in Acer Therapeutics Inc in Q4 2013 and held it in 1 quarter.
  • Sophrosyne Capital's Acer Therapeutics Inc position peaked at $366K in Q4 2013.
  • 18 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q1 2014.

Based on Sophrosyne Capital's 13F filing for Q1 2014, filed 14 May 2014.